168 related articles for article (PubMed ID: 35889320)
1. Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir.
Qureshi A; Ouattara LA; El-Sayed NS; Verma A; Doncel GF; Choudhary MI; Siddiqui H; Parang K
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889320
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
Cox S; Margot N; Callebaut C
J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
[TBL] [Abstract][Full Text] [Related]
4. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
5. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
[No Abstract] [Full Text] [Related]
8. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
[TBL] [Abstract][Full Text] [Related]
9. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
10. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
11. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
12. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
13. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models.
Hong X; Cai Z; Zhou F; Jin X; Wang G; Ouyang B; Zhang J
Front Pharmacol; 2022; 13():932934. PubMed ID: 36105197
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir alafenamide fumarate.
Lee WA; Cheng AK
Antivir Ther; 2022 Apr; 27(2):13596535211067600. PubMed ID: 35499175
[TBL] [Abstract][Full Text] [Related]
15. Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors.
Costa-Tuna A; Chaves OA; Almeida ZL; Cunha RS; Pina J; Serpa C
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675834
[TBL] [Abstract][Full Text] [Related]
16. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Bukkems VE; Necsoi C; Hidalgo Tenorio C; Garcia C; Alba Alejandre I; Weiss F; Lambert JS; van Hulzen A; Richel O; Te Brake LHM; van der Meulen E; Burger D; Konopnicki D; Colbers A
Clin Infect Dis; 2022 Sep; 75(4):623-629. PubMed ID: 34864950
[TBL] [Abstract][Full Text] [Related]
19. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Ray AS; Fordyce MW; Hitchcock MJ
Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
